STYK1

Summary

STYK1 (serine/threonine/tyrosine kinase 1, HGNC:18889) is a protein-coding gene on chromosome 12p13.2, encoding Tyrosine-protein kinase STYK1 (Q6J9G0). Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines.

Receptor protein tyrosine kinases, like STYK1, play important roles in diverse cellular and developmental processes, such as cell proliferation, differentiation, and survival (Liu et al., 2004 [PubMed 15150103]).

Source: NCBI Gene 55359 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 76 total
• MANE Select transcript: NM_018423

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18889
Approved symbol	STYK1
Name	serine/threonine/tyrosine kinase 1
Location	12p13.2
Locus type	gene with protein product
Status	Approved
Aliases	SuRTK106, DKFZp761P1010, NOK
Ensembl gene	ENSG00000060140
Ensembl biotype	protein_coding
OMIM	611433
Entrez	55359

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 19 protein_coding

ENST00000075503, ENST00000535345, ENST00000538867, ENST00000541561, ENST00000542562, ENST00000542924, ENST00000878937, ENST00000878938, ENST00000878939, ENST00000878940, ENST00000878941, ENST00000878942, ENST00000878943, ENST00000878944, ENST00000878945, ENST00000954950, ENST00000954951, ENST00000954952, ENST00000954953

RefSeq mRNA: 1 — MANE Select: NM_018423 NM_018423

CCDS: CCDS8629

Canonical transcript exons

ENST00000075503 — 11 exons

Exon	Start	End
ENSE00000482411	10624651	10624859
ENSE00000720554	10621876	10621972
ENSE00000720574	10622638	10622678
ENSE00000720575	10627641	10627724
ENSE00000720576	10629493	10629674
ENSE00000720578	10631045	10631308
ENSE00000720579	10633990	10634124
ENSE00001145475	10618923	10620348
ENSE00001145482	10634567	10634686
ENSE00001161001	10637071	10637196
ENSE00001161009	10673966	10674052

Expression profiles

Bgee: expression breadth ubiquitous, 219 present calls, max score 97.10.

FANTOM5 (CAGE): breadth broad, TPM avg 0.7208 / max 19.4437, expressed in 353 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129536	0.7208	353

Top tissues by expression

273 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	97.10	gold quality
amniotic fluid	UBERON:0000173	95.37	gold quality
pancreatic ductal cell	CL:0002079	93.45	gold quality
esophagus squamous epithelium	UBERON:0006920	91.01	gold quality
rectum	UBERON:0001052	86.04	gold quality
middle temporal gyrus	UBERON:0002771	85.58	gold quality
epithelial cell of pancreas	CL:0000083	84.96	silver quality
epithelium of esophagus	UBERON:0001976	84.54	gold quality
Brodmann (1909) area 23	UBERON:0013554	84.24	gold quality
squamous epithelium	UBERON:0006914	83.87	gold quality
colonic mucosa	UBERON:0000317	83.70	gold quality
mucosa of transverse colon	UBERON:0004991	83.63	gold quality
mucosa of sigmoid colon	UBERON:0004993	83.55	gold quality
palpebral conjunctiva	UBERON:0001812	83.18	gold quality
lower esophagus mucosa	UBERON:0035834	82.01	gold quality
esophagus mucosa	UBERON:0002469	79.62	gold quality
cervix squamous epithelium	UBERON:0006922	79.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.25	gold quality
epithelium of nasopharynx	UBERON:0001951	78.25	gold quality
prefrontal cortex	UBERON:0000451	78.08	gold quality
nasal cavity epithelium	UBERON:0005384	77.67	gold quality
secondary oocyte	CL:0000655	77.08	gold quality
minor salivary gland	UBERON:0001830	77.00	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.83	gold quality
bronchial epithelial cell	CL:0002328	76.25	gold quality
transverse colon	UBERON:0001157	76.21	gold quality
nasal cavity mucosa	UBERON:0001826	75.89	gold quality
type B pancreatic cell	CL:0000169	75.61	gold quality
olfactory bulb	UBERON:0002264	75.50	gold quality
primary visual cortex	UBERON:0002436	75.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

71 targeting STYK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-577	99.78	69.13	2479
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-4677-5P	99.70	70.09	1940
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-1287-3P	99.63	66.93	492
HSA-MIR-4499	99.62	67.29	1470
HSA-MIR-3153	99.55	67.59	2337

Literature-anchored findings (GeneRIF, showing 27)

• SuRTK106/NOK/STYK1 was first identified, classified and shown to have predicted pseudokinase domain. (PMID:12471243)
• cloning and characterization; mapped to chromosome 12p13; widely expressed in human tissues (PMID:12841579)
• NOK mRNA was highly expressed even at the early clinical stages of the cancer. These results suggest that NOK mRNA might be a new tool to support the diagnosis of lung cancers, irrespective of the clinical stages. (PMID:17298854)
• The regulation of STYK1/NOK is achieved independent of ERalpha and suggests further investigation to the relevance of this kinase in breast cancer progression. (PMID:17415682)
• results indicate that STYK1/NOK mRNA is widely expressed in the patients with acute leukemia and suggest that inhibition of this molecule could potentially serve as a novel therapeutic target (PMID:19409952)
• Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer. (PMID:19664042)
• Taken together, NOK has a strong tendency towards forming aggregates, which may have physiological implications and provide the first evidence that this novel receptor kinase is colocalised with EGFR in endosomes to participate in a post-internalisation step of EGFR. (PMID:22516751)
• The expression levels of NOK, p-Akt(Thr308) and p-GSK-3beta(Ser9) were positively correlated in cancerous and non-cancerous breast cell lines. (PMID:23010592)
• Our results indicate that NOK expression is of clinical significance and can serve as a prognostic biomarker in non-small cell lung cancer. (PMID:24894011)
• STYK1/NOK is dramatically upregulated in colorectal cancer tissues and could be used as a tumor marker. Furthermore, the high expression of STYK1/NOK is significantly associated with tumor size. (PMID:25169509)
• These results suggest that STYK1 is a novel drug resistance factor and could be a predictor of the therapeutic response in acute leukemia. (PMID:25190507)
• increased STYK1 protein expression correlates with disease progression and metastasis and may serve as a predictor of poor survival in CRC. (PMID:25884558)
• The data indicates that both P203 and V395 residues on NOK are important for NOK mediated mitogenic signaling. (PMID:25961552)
• NOK expression increased in renal cell carcinoma and was significantly correlated with TNM stage, Fuhrman grade, poor overall survival, poor disease-free survival, metastasis, and proliferation. (PMID:27012048)
• Thus, our results reveal a novel tumorigenic function of NOK to mediate the genesis and remodeling of blood and lymphatic vessels during tumor progression. (PMID:27444381)
• High STYK1 expression is associated with intrahepatic cholangiocarcinoma. (PMID:27542675)
• Overexpression of STYK1 was significantly associated with increased cell proliferation, migratory capability, and invasive capability in vitro, as well as increased volume of tumor, weight of tumor, and number of pulmonary metastasesin hepatocellular carcinoma. (PMID:27628214)
• STYK1 plays an important role in glioma development and progression. (PMID:27983928)
• Findings show that serine-threonine-tyrosine kinase 1 (NOK) mediates glycolysis and nuclear pyruvate dehydrogenase complex (PDC) associated histone acetylation. (PMID:28410146)
• Survival analysis reveals that STYK1 level is an independent prognostic factor for nasopharyngeal carcinoma patients. Our results indicate that STYK1 is a promising therapeutic target in nasopharyngeal carcinoma (PMID:28720063)
• findings suggest that STYK1 is a critical regulator of tumor growth and metastasis. (PMID:29413947)
• SMAD3 induces the transcription of STYK1 to promote epithelial-mesenchymal transition and to elicit paclitaxel resistance of ovarian cancer cells. (PMID:30701575)
• elevated serine threonine tyrosine kinase 1 (STYK1) or decreased serine peptidase inhibitor Kunitz type 2 (SPINT2/HAI-2) expression significantly correlated with poor prognosis, tumor invasion, and metastasis of NSCLC patients. STYK1 overexpression promoted NSCLC cells proliferation, migration, and invasion. STYK1 also induced epithelial-mesenchymal transition by E-cadherin downregulation and Snail upregulation. (PMID:31164631)
• Data suggest that regulating ferroptosis could be another cancerous mechanism of serine/threonine/tyrosine kinase 1 (STYK1). (PMID:31542233)
• STYK1 promotes the malignant progression of laryngeal squamous cell carcinoma through targeting TGF-beta1. (PMID:32572882)
• NOK associates with c-Src and promotes c-Src-induced STAT3 activation and cell proliferation. (PMID:32871210)
• Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice. (PMID:35970044)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	styk1b	ENSDARG00000041947
mus_musculus	Styk1	ENSMUSG00000032899
rattus_norvegicus	Styk1	ENSRNOG00000010347
caenorhabditis_elegans		WBGENE00012632

Paralogs (32): FGR (ENSG00000000938), MATK (ENSG00000007264), BTK (ENSG00000010671), FYN (ENSG00000010810), TNK2 (ENSG00000061938), TXK (ENSG00000074966), JAK2 (ENSG00000096968), ABL1 (ENSG00000097007), PTK6 (ENSG00000101213), HCK (ENSG00000101336), BMX (ENSG00000102010), CSK (ENSG00000103653), TYK2 (ENSG00000105397), JAK3 (ENSG00000105639), FRK (ENSG00000111816), ITK (ENSG00000113263), ZAP70 (ENSG00000115085), PTK2B (ENSG00000120899), SRMS (ENSG00000125508), TEC (ENSG00000135605), BLK (ENSG00000136573), ABL2 (ENSG00000143322), FER (ENSG00000151422), JAK1 (ENSG00000162434), SYK (ENSG00000165025), PTK2 (ENSG00000169398), TNK1 (ENSG00000174292), YES1 (ENSG00000176105), FES (ENSG00000182511), LCK (ENSG00000182866), SRC (ENSG00000197122), LYN (ENSG00000254087)

Protein

Protein identifiers

Tyrosine-protein kinase STYK1 — Q6J9G0 (reviewed: Q6J9G0)

Alternative names: Novel oncogene with kinase domain, Protein PK-unique, Serine/threonine/tyrosine kinase 1

All UniProt accessions (6): Q6J9G0, F5GZF6, F5H2I9, F5H366, F5H4G3, H0YGL5

UniProt curated annotations — full annotation on UniProt →

Function. Probable tyrosine protein-kinase, which has strong transforming capabilities on a variety of cell lines. When overexpressed, it can also induce tumor cell invasion as well as metastasis in distant organs. May act by activating both MAP kinase and phosphatidylinositol 3’-kinases (PI3K) pathways.

Subcellular location. Membrane.

Tissue specificity. Widely expressed. Highly expressed in brain, placenta and prostate. Expressed in tumor cells such as hepatoma cells L-02, cervix carcinoma cells HeLa, ovary cancer cells Ho8910 and chronic myelogenous leukemia cells K-562, but not in other tumor cells such as epidermoid carcinoma (A-431). Undetectable in most normal lung tissues, widely expressed in lung cancers.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family.

RefSeq proteins (1): NP_060893* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR050122	RTK	Family

Pfam: PF07714

Catalyzed reactions (Rhea), 1 shown:

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (15 total): sequence variant 7, sequence conflict 2, binding site 2, chain 1, transmembrane region 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6J9G0-F1	84.20	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 251 (proton acceptor)

Ligand- & substrate-binding residues (2): 120–128; 147

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 106 (showing top): BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP, GOMF_PROTEIN_KINASE_ACTIVITY, GOMF_KINASE_ACTIVITY, GOMF_NON_MEMBRANE_SPANNING_PROTEIN_TYROSINE_KINASE_ACTIVITY, MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_TRANSFERASE_ACTIVITY_TRANSFERRING_PHOSPHORUS_CONTAINING_GROUPS, ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP, WAMUNYOKOLI_OVARIAN_CANCER_LMP_UP, JOHNSTONE_PARVB_TARGETS_3_DN, WINZEN_DEGRADED_VIA_KHSRP, ANDERSEN_CHOLANGIOCARCINOMA_CLASS2, ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, NFE2L2.V2

GO Biological Process (1): protein phosphorylation (GO:0006468)

GO Molecular Function (8): non-membrane spanning protein tyrosine kinase activity (GO:0004715), ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein tyrosine kinase activity (GO:0004713), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
phosphorylation	1
protein modification process	1
protein tyrosine kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
protein kinase activity	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

648 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
STYK1	PALS2	Q9NZW5	762
STYK1	PALS1	Q8N3R9	693
STYK1	LIN7A	O14910	650
STYK1	PATJ	Q8NI35	635
STYK1	NSMCE1	Q8WV22	431
STYK1	MPP1	Q00013	426
STYK1	ITPKA	P23677	394
STYK1	TMEM239	Q8WW34	392
STYK1	OR2T5	Q6IEZ7	372
STYK1	MAGOHB	Q96A72	361
STYK1	TMC7	Q7Z402	360
STYK1	MLF2	Q15773	338
STYK1	SSBP2	P81877	334
STYK1	TMC6	Q7Z403	331
STYK1	IPP	Q9Y573	315

IntAct

10 interactions, top by confidence:

A	B	Type	Score
GSK3B	AKT1	psi-mi:“MI:0914”(association)	0.830
HSP90AB1	STYK1	psi-mi:“MI:0915”(physical association)	0.670
STYK1	GSK3B	psi-mi:“MI:0915”(physical association)	0.500
STYK1	XPO1	psi-mi:“MI:0914”(association)	0.350
STYK1	MYO1C	psi-mi:“MI:0914”(association)	0.350
STYK1	HSP90AB4P	psi-mi:“MI:0914”(association)	0.350
STYK1	MYO1F	psi-mi:“MI:0914”(association)	0.350
CACNG4	TTI1	psi-mi:“MI:0914”(association)	0.350
STYK1	FAM171A2	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (185): STYK1 (PCA), STYK1 (Protein-RNA), ATG14 (Affinity Capture-Western), BECN1 (Affinity Capture-Western), PIK3C3 (Affinity Capture-Western), PIK3R4 (Affinity Capture-Western), GNB2L1 (Affinity Capture-Western), NRBF2 (Affinity Capture-Western), STYK1 (Affinity Capture-Western), STYK1 (Affinity Capture-Western), BECN1 (Co-localization), PIK3C3 (Co-localization), PIK3R4 (Co-localization), BECN1 (Reconstituted Complex), PIK3C3 (Reconstituted Complex)

ESM2 similar proteins: G5EE56, O13147, O13148, O45539, P00523, P00524, P00525, P00526, P00528, P00529, P04048, P09769, P13115, P13116, P14084, P14085, P14234, P16277, P17713, P22182, P25020, P31693, P32577, P35991, P41239, P41240, P41241, P42680, P42681, P42682, P42685, P42686, P42690, P51451, P63185, P97504, Q03526, Q06187, Q08881, Q0VBZ0

Diamond homologs: A0M8R7, A0M8S8, A1X150, D2IYS2, G3V9H8, O42127, O45539, O76997, P00519, P00520, P00521, P00522, P03949, P06239, P07949, P08581, P08630, P08631, P09760, P10447, P11362, P16092, P18460, P21804, P22182, P22455, P22607, P23049, P32577, P33497, P35546, P35590, P35739, P41239, P41240, P41241, P42684, P42685, P42686, P42688

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
STYK1	“up-regulates activity”	BECN1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1652 predictions. Top by Δscore:

Variant	Effect	Δscore
12:10620349:CT:C	acceptor_loss	1.0000
12:10621871:CTTA:C	donor_loss	1.0000
12:10621872:TTA:T	donor_loss	1.0000
12:10621873:TA:T	donor_loss	1.0000
12:10621874:A:AC	donor_gain	1.0000
12:10621874:ACATG:A	donor_loss	1.0000
12:10621875:C:CA	donor_loss	1.0000
12:10621875:C:CC	donor_gain	1.0000
12:10621875:CA:C	donor_gain	1.0000
12:10621875:CAT:C	donor_gain	1.0000
12:10621875:CATG:C	donor_gain	1.0000
12:10621875:CATGG:C	donor_gain	1.0000
12:10621970:CTC:C	acceptor_gain	1.0000
12:10621973:C:A	acceptor_loss	1.0000
12:10621973:C:CC	acceptor_gain	1.0000
12:10621979:T:TC	acceptor_gain	1.0000
12:10624629:AGAGT:A	donor_gain	1.0000
12:10624650:CA:C	donor_gain	1.0000
12:10624650:CACAT:C	donor_gain	1.0000
12:10624654:T:C	donor_gain	1.0000
12:10627721:CATC:C	acceptor_gain	1.0000
12:10627723:TC:T	acceptor_gain	1.0000
12:10627723:TCCTA:T	acceptor_loss	1.0000
12:10627724:CC:C	acceptor_gain	1.0000
12:10627725:C:CC	acceptor_gain	1.0000
12:10627725:CTAA:C	acceptor_loss	1.0000
12:10627726:T:C	acceptor_loss	1.0000
12:10634138:C:CT	acceptor_gain	1.0000
12:10634140:C:CT	acceptor_gain	1.0000
12:10620349:C:CC	acceptor_gain	0.9900

AlphaMissense

2743 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:10624703:A:G	W292R	0.992
12:10624703:A:T	W292R	0.992
12:10622652:T:A	E318V	0.986
12:10622677:A:G	W310R	0.984
12:10622677:A:T	W310R	0.984
12:10622668:C:A	G313W	0.982
12:10624701:C:A	W292C	0.980
12:10624701:C:G	W292C	0.980
12:10624816:G:T	A254D	0.980
12:10629497:C:G	R210P	0.979
12:10622651:C:A	E318D	0.977
12:10622651:C:G	E318D	0.977
12:10622652:T:G	E318A	0.977
12:10622661:A:G	L315P	0.977
12:10624704:C:A	K291N	0.977
12:10624704:C:G	K291N	0.977
12:10622667:C:T	G313E	0.976
12:10620327:G:C	C362W	0.975
12:10624820:C:G	A253P	0.974
12:10621972:C:T	G323E	0.973
12:10620305:G:T	R370S	0.971
12:10621972:C:A	G323V	0.971
12:10627664:C:G	G232R	0.971
12:10627664:C:T	G232R	0.971
12:10620329:A:G	C362R	0.970
12:10621963:G:T	P326Q	0.970
12:10620326:A:G	W363R	0.969
12:10620326:A:T	W363R	0.969
12:10627642:A:G	L239P	0.969
12:10622649:A:C	M319R	0.968

dbSNP variants (sampled 300 via entrez): RS1000013879 (12:10658050 T>C), RS1000049330 (12:10664595 G>A), RS1000059472 (12:10665181 T>A), RS1000114283 (12:10638728 C>T), RS1000132673 (12:10621766 G>A,T), RS1000150420 (12:10631535 C>T), RS1000208120 (12:10622055 G>T), RS1000241836 (12:10652481 A>G), RS1000270463 (12:10642401 C>T), RS1000390084 (12:10635125 A>C), RS1000421873 (12:10622935 T>C), RS1000546291 (12:10658688 A>G), RS1000633987 (12:10647663 G>A), RS1000680932 (12:10654905 A>G), RS1000764807 (12:10647992 C>G)

Disease associations

OMIM: gene MIM:611433 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type XX RTKs: STYK1

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases methylation	7
trichostatin A	increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
Panobinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases expression	2
Copper	affects cotreatment, decreases expression, affects binding, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	increases expression	1
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
pentanal	increases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	increases expression, affects binding	1
Bortezomib	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Aldehydes	increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Drugs, Chinese Herbal	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TR15	HAP1 STYK1 (-) 1	Cancer cell line	Male
CVCL_TR16	HAP1 STYK1 (-) 2	Cancer cell line	Male
CVCL_TR17	HAP1 STYK1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.